SCHEMBL1763180

SCHEMBL1763180

O=C(O)c1ccc(C2CCN(C(=O)OCc3ccccc3)CC2)c(C(F)(F)F)c1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
SLC9A1 P19634 11/20 0.52
CYP2C19 P33261 7/20 0.52
CYP2C9 P11712 6/20 0.52
RBP4 P02753 4/20 0.49
CYP3A4 P08684 4/20 0.48
ADRA1D P25100 1/20 0.48
HTR2A P28223 1/20 0.48
SLC6A3 Q01959 1/20 0.48
SLC9A2 Q9UBY0 1/20 0.48
CYP2D6 P10635 2/20 0.47
HTT P42858 1/20 0.47
MRGPRX4 Q96LA9 1/20 0.47
KCNH2 Q12809 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1764080 0.90 RBP4 (0.61) SMN1; SMN2NPC1RAB9ASLC9A1CYP2C19
SCHEMBL7838902 0.81 SMN1; SMN2 (0.54) SMN1; SMN2NPC1RAB9ACYP2C19CYP2C9
SCHEMBL19404809 0.81 RBP4 (0.59) SMN1; SMN2NPC1RAB9ACYP2C19RBP4
SCHEMBL1763737 0.81 SLC9A1 (0.54) SLC9A1CYP2C19CYP2C9CYP3A4ADRA1D
SCHEMBL6825112 0.80 SMN1; SMN2 (0.51) SMN1; SMN2NPC1RAB9ACYP2C19CYP2C9
SCHEMBL1763271 0.78 RBP4 (0.72) SMN1; SMN2RAB9ASLC9A1CYP2C19CYP2C9
SCHEMBL8316925 0.77 SMN1; SMN2 (0.61) SMN1; SMN2NPC1RAB9ACYP2C19CYP2C9
SCHEMBL7666258 0.77 SMN1; SMN2 (0.55) SMN1; SMN2NPC1RAB9ACYP2C19CYP2C9
SCHEMBL31188362 0.76 SLC9A1 (0.50) SLC9A1CYP2C19CYP2C9RBP4CYP3A4
SCHEMBL1763934 0.76 SLC9A1 (0.54) SLC9A1CYP2C19CYP2C9RBP4CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118262-A1 Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-19 US disclosed
EP-2321274-A1 PYRROLIDINYL AND PIPERIDINYL COMPOUNDS USEFUL AS NHE-1 INHIBITORS Boehringer Ingelheim International GmbH (DE) 2011-05-18 EP disclosed
WO-2010005783-A1 PYRROLIDINYL AND PIPERIDINYL COMPOUNDS USEFUL AS NHE-1 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118262-A1 Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors NHERF1, SLC9A1, SLC9A5 SMN1; SMN2 4454/4885NPC1 236/4885RAB9A 698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.